Company intelligence / Profile preview

Forendo Pharma

Turku, Finland

Ownership: Private
Development stage: Phase 2

Overview

Forendo Pharma developed first-in-class oral small molecule therapies targeting tissue-specific hormone regulation. Its lead candidate, FOR‑6219, an HSD17B1 inhibitor for endometriosis, entered Phase II trials. A second preclinical program targeted PCOS. The company also had a strategic collaboration with Novartis on chronic liver disease using its HSD17B platform. In December 2021, Organon acquired the company to expand its women’s health pipeline.

Therapeutic areas: GastroenterologyWomen's HealthEndocrinologyMen's Health
Modalities: small molecules
Industry: Biotech

Drug pipeline

3 assets

GB0139

Phase 2

Indications: Idiopathic pulmonary fibrosis

2 more assets in the full pipeline.

Request access →

Partnerships

Novartis – strategic collaboration leveraging HSD17B platform in chronic liver diseases

Beyond the preview

Go deeper on Forendo Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forendo Pharma.

Explore the full profile